Amgen Ltd

Information

Name

Amgen Ltd

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

http://www.amgen.com

Address

Cambridge

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Amgen Ltd
Sign up free

Contracts awarded to Amgen Ltd

The contracts that Amgen Ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 1 month ago

CM/TNS/24/5711 -NHS Framework for the supply of Ustekinumab

Project title: NHS National Framework for the supply of Ustekinumab 1 September 2024 Offer reference number: CM/TNS/24/5711 CM/TNS/24/5711/01 - NHS Framework for the supply of Ustekinumab - London & South of England. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/TNS/24/5711/02 - NHS Framework for the supply of Ustekinumab - North of England and Midlands & East. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£230,000,000 Bids close: 4 months ago
Award

Published 1 month ago

NHS National Framework for the supply of Ustekinumab - 1 September 2024

Project title: NHS National Framework for the supply of Ustekinumab 1 September 2024 Offer reference number: CM/TNS/24/5711 CM/TNS/24/5711/01 - NHS Framework for the supply of Ustekinumab - London & South of England. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/TNS/24/5711/02 - NHS Framework for the supply of Ustekinumab - North of England and Midlands & East. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£12
Award

Published 1 month ago

Ustekinumab and Omalizumab

Supply of Ustekinumab and Omalizumab to NHS Scotland

£13,816,578
Award

Published 6 months ago

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Offer reference number: CM/PHR/22/5682 CM/PHR/22/5682/01 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 1. Period of framework: 1 May 2024 to 30 April 2028. CM/PHR/22/5682/02 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 2. Period of framework: 1 May 2024 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Bids close: 11 months ago
Award

Published 6 months ago

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Offer reference number: CM/PHR/22/5682 CM/PHR/22/5682/01 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 1. Period of framework: 1 May 2024 to 30 April 2028. CM/PHR/22/5682/02 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 2. Period of framework: 1 May 2024 to 30 April 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£92
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months

£74

Contacts

[email protected]

+44 1223436406

Statistics (1 Year)

Contracts Won

Total Won

£68,943,470

Average Win

£22,981,157

Amgen Ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Amgen Ltd

CM/TNS/24/5711 -NHS Framework for the supply of Ustekinumab

NHS National Framework for the supply of Ustekinumab - 1 September 2024

Ustekinumab and Omalizumab

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win